Pharmaceutical Executive-03-01-2022

Study analyzes mainstream media coverage of the industry before and after the COVID-19 lockdown.

Full-year business review of pharma and biotech sectors reveals strong momentum in advancing novel science and treatments, but likely foretells continued stock instability in near-to-medium terms.

Despite disruption from the COVID-19 pandemic still in full swing, life sciences innovation activity remained undeterred, a recent report from the IQVIA Institute for Human Data Science finds—outlining the key factors driving record-breaking growth.

Pharma and legal experts weigh in on the rush to secure intellectual property around psychedelic medicines, the value imperative that should govern pricing strategies, and the likely long-haul battle for more widespread decriminalization of these drugs.

A look at the renewed efforts of biopharma companies in exploring age-old substances to treat mental health conditions and more, minus the negative effects.

After helping lead Novo Nordisk on a transformational journey from a troubled 2016 to double-digit growth in 2021, Doug Langa, Executive Vice President, Head of North America Operations and President of Novo Nordisk, Inc., is calling on his experience of taking the less conventional and sometimes unexpected routes to success to lead Novo Nordisk into new territory.

But a doubling-down on R&D offers reason for optimism.

Connected TV advertising now a critical component of media mix.

A new report examining pharma sector exposure makes for sobering reading, especially in US.

For pharma teams, reaping the talent benefits requires skillful oversight.

Efforts for a standardized approach coming to a head in Europe.

Prior experiences in pharma and handling of opioid epidemic offer valuable lessons.

Click the title above for a link to open the Pharmaceutical Executive March 2022 issue in an interactive PDF format.

Pressurized political, COVID climates greet his return to top spot.